Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 9,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Arm Clear all
Completed Phase 2 Interventional Results available

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

NCT01314118
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasm
Interventions
abiraterone acetate in combination with prednisone
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
45
States / cities
Homewood, Alabama • Huntsville, Alabama • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 23, 2026, 6:22 PM EDT
Recruiting Phase 2 Interventional

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

NCT06417190
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Tumor
Interventions
Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)
Drug
Lead sponsor
Leslie Ballas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 6:22 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

NCT05885464
View directory record Official record
Conditions
Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
Interventions
BEAM-201
Biological
Lead sponsor
Beam Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Stanford, California • Denver, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 23, 2026, 6:22 PM EDT
Completed Not applicable Interventional Results available

The ShortCut™ Study Protocol

NCT04952909
View directory record Official record
Conditions
Risk of Coronary Obstruction Following Transcatheter Aortic Valve Replacement (TAVR) Procedure
Interventions
ShortCut™
Device
Lead sponsor
Pi-cardia
Industry
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 23, 2026, 6:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IV Iron Safety: Evaluation of Iron Species in Healthy Subjects

NCT02399449
View directory record Official record
Conditions
Anemia
Interventions
Brand sodium ferric gluconate, Generic sodium ferric gluconate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 23, 2026, 6:22 PM EDT
Completed Phase 1 Interventional

A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors

NCT03099109
View directory record Official record
Conditions
Solid Tumor
Interventions
LY3321367, LY3300054
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
8
States / cities
Tucson, Arizona • Boston, Massachusetts • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 23, 2026, 6:22 PM EDT
Completed Phase 3 Interventional Results available

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT05136898
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Homewood, Alabama • Indianapolis, Indiana • Greensboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 6:22 PM EDT
Not yet recruiting Not applicable Interventional

The TERUMO FRED X EARLY FEASIBILITY STUDY (FAST) STUDY.

NCT07761598
View directory record Official record
Conditions
Aneurysm Cerebral
Interventions
Fred X Medical Device Intervention for Aneurysm Treatment with DAPT Therapy.
Device
Lead sponsor
Jacobs institute
Other
Eligibility
22 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 6:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Neurobiology of Expectancy and Pain Perception

NCT01575106
View directory record Official record
Conditions
Pain
Interventions
Heat pain applied using TSA or CHEPS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 50 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 23, 2026, 6:22 PM EDT
Completed Phase 1 Interventional Results available

AMD 3100 for Treatment of Myelokathexis

NCT01058993
View directory record Official record
Conditions
Neutropenia
Interventions
AMD3100 or plerixafor
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 15, 2012 · Synced Oct 23, 2026, 6:22 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

NCT03737214
View directory record Official record
Conditions
Fabry Disease
Interventions
Lucerastat
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
14
States / cities
Birmingham, Alabama • Irvine, California • Oakland, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 23, 2026, 6:22 PM EDT
Terminated Phase 3 Interventional Results available

Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders

NCT02266433
View directory record Official record
Conditions
DeQuervains Tenosynovitis, Lateral Epicondylitis, Tennis Elbow, Trigger Finger, Tenosynovitis, Inflammatory Disease
Interventions
Ketorolac, Dexamethasone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 23, 2026, 6:22 PM EDT
Not listed Not applicable Interventional

Safety and Effectiveness Study of the Zenflow Spring System

NCT04987138
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Interventions
Zenflow Spring System, Sham Procedure
Device
Lead sponsor
Zenflow, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Glenview, Illinois • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 23, 2026, 6:22 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

NCT04864392
View directory record Official record
Conditions
Osteoarthritis
Interventions
LNA043, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 23, 2026, 6:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Examining the Most Effective Method to Reduce Running Ground Contact Time

NCT06988709
View directory record Official record
Conditions
Healthy Runners
Interventions
Real-time Visual Feedback, Real-time Auditory Feedback, Real-time Verbal Feedback
Other
Lead sponsor
Keller Army Community Hospital
Federal
Eligibility
17 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
West Point, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 6:22 PM EDT
Terminated Not applicable Interventional Results available

Intraarticular Corticosteroid Therapy in Perthes Disease.

NCT01026909
View directory record Official record
Conditions
Legg-Calve Perthes Disease
Interventions
Aristospan 20mg
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
4 Years to 13 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 23, 2026, 6:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis

NCT06461299
View directory record Official record
Conditions
Perioral Dermatitis
Interventions
Seysara Oral Product
Drug
Lead sponsor
The Dermatology Institute of Boston
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 23, 2026, 6:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleep Self-management in Pregnancy Using a Personalized Health Monitoring Device

NCT03783663
View directory record Official record
Conditions
Pregnancy, Sleep
Interventions
Misfit Shine 2
Behavioral
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 23, 2026, 6:22 PM EDT
Terminated Phase 2 Interventional

A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.

NCT00179738
View directory record Official record
Conditions
Prostate Cancer
Interventions
CC5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
Berkeley, California • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2005 · Synced Oct 23, 2026, 6:22 PM EDT
Completed Not applicable Interventional

Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With PD Undergoing Deep Brain Stimulation

NCT01833364
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Implantation of the Peripheral Nerve Graft
Procedure
Lead sponsor
Craig van Horne, MD, PhD
Other
Eligibility
40 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 23, 2026, 6:22 PM EDT
Completed Not applicable Interventional Results available

Prophylactic Maze to Prevent Atrial Fibrillation in Adult Cardiac Surgery

NCT03604432
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
propylactic maze
Device
Lead sponsor
Corewell Health West
Other
Eligibility
70 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 23, 2026, 6:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of an ADAPTive Intervention to Improve Food Security and Maternal-Child Health

NCT06942598
View directory record Official record
Conditions
Food Insecurity, Pregnancy
Interventions
Produce prescription, Medically tailored meals, Electronic health record WIC referral, Electronic health record WIC referral + care navigation
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 6:22 PM EDT
Recruiting Not applicable Interventional

Wearable Device and Behavioral Support for Enhancing Arm Use After Stroke

NCT07042152
View directory record Official record
Conditions
Chronic Stroke Patients
Interventions
Smartwatch App for Movement Variability, Smartwatch App for Active Time, Motivational Interviewing (Within Subjects)
Other · Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 84 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 23, 2026, 6:22 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

NCT04663347
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, Rituximab and Lenalidomide, rituximab and bendamustine, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, gemcitabine and oxaliplatin, Epcoritamab, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate
Drug · Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 6:22 PM EDT